ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2498

Biomarkers of Mitochondrial Dysfunction Correlate with Disease Activity in SLE

Zhi-Wei Lai1, Tiffany Telarico2, Robert Hanczko1, Adam Bartos1, Lisa Francis3, Hajra I. Tily4, Ricardo Garcia1, Maha M. Dawood5, Jianghong Yu6, Ashwini Shadakshari6, Paul E. Phillips7 and Andras Perl8, 1Medicine, SUNY, Syracuse, NY, 2Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Medicine/Rheumatology, SUNY upstate medical university, Syracuse, NY, 4SUNY, NY, 5Medicine/Rheumatology, SUNY Upstate, Syracuse, NY, 6Medicine/Rheumatology, SUNY Upstate Medical University, Syracuse, NY, 7Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, 8Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, mitochondria and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic lupus erythematosus (SLE) patients’ T cells exhibit mitochondrial dysfunction, characterized by the persistent elevation of the mitochondrial transmembrane potential (Δψm) or mitochondrial hyperpolarization (MHP), that predisposes to oxidative stress, activation of the mammalian target of rapamycin (mTOR), and pro-inflammatory death via necrosis. Here, we evaluated metabolic checkpoints of mitochondrial dysfunction as biomarkers of disease activity in patients with SLE.

Methods:

49 female SLE patients and 41 female healthy controls were matched for 209 independent study visits. SLE disease activity was assessed by using the British Isles Lupus Assessment Group (BILAG), SLE Disease Activity Index (SLEDAI), and Fatigue Assessment Scale (FAS). Peripheral blood lymphocytes (PBL) and untouched T cells (using Dynal negative T-cell isolation kit) were freshly isolated on the same morning from patients and controls matched for ethnicity and age within 10 years and investigated in parallel for Δψm, mitochondrial mass, glutathione, NO and ROI production, cytosolic ([Ca2+]c) and mitochondrial calcium levels ([Ca2+]m), T and B cell subset distribution, and mTOR activity by flow cytometry with or without CD3/CD28 co-stimulation.

Results:

The SLEDAI (9.8 ± 0.5), BILAG (25.0 ±0.7) and FAS (26.3 ±0.4) scores showed significant correlations (SLEDAI and BILAG scores: r = 0.5138; p = 0.0014;. FAS and SLEDAI: r = 0.3570; p = 0.0326; FAS and BILAG, r = 0.4341; p = 0.0082). SLEDAI positively correlated with necrotic T cells (r = 0.383; p=0.007), necrotic CD4+ T cells (r = 0.418; p=0.003), and necrotic CD4-/CD8- double negative (DN) T cells (r = 0.347; p=0.016). SLEDAI negatively correlated with Foxp3+/CD25+/CD4+ Tregs (r = -0.293; p=0.043) and CD3/CD28-induced mTOR activation in CD4+ (r = -0.310; p=0.032) and CD8+ T cells (r = -0.410; p=0.004). Among the immunological biomarkers of SLEDAI, C3 negatively correlated with viable CD8+ T cells (r = -0.388; p=0.008) and positively correlated with viable CD4+ T cells (r = 0.405; p=0.005) . C4 negatively correlated with MHP of T cells (r = -0.370; p=0.011) and DN T cells by TMRM fluorescence (r = -0.428; p=0.003). C4 positively correlated with viable CD4+ T cells (r = 0.302; p=0.041) and necrotic CD8+ T cells (r = 0.307; p=0.038). Anti-DNA positively correlated with the increased mitochondrial mass in DN T cells (r = 0.438; p=0.002), increased H2O2 levels in CD8+ T cells (r = 0.447; p=0.002), and increased [Ca2+]c in T cells (r = 0.480; p=0.001), CD4+ T cells (r = 0.467; p=0.001), CD8+ T cells (r = 0.487; p=0.001), DN T cells (r = 0.456; p=0.001),  and CD19+ B cells (r = 0.432; p=0.003). 

Conclusion:

MHP, necrosis rate, and [Ca2+]c, particularly in DN T cells, represent biomarkers of disease activity in patients with SLE.


Disclosure:

Z. W. Lai,
None;

T. Telarico,
None;

R. Hanczko,
None;

A. Bartos,
None;

L. Francis,
None;

H. I. Tily,
None;

R. Garcia,
None;

M. M. Dawood,
None;

J. Yu,
None;

A. Shadakshari,
None;

P. E. Phillips,
None;

A. Perl,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-of-mitochondrial-dysfunction-correlate-with-disease-activity-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology